Covid-19 roundup: Re­searchers urge Pfiz­er to adopt high safe­ty stan­dard, hold vac­cine EUA un­til late No­vem­ber

Pfiz­er has been the on­ly play­er in the glob­al Covid-19 vac­cine race that’s pre­dict­ed that it will know whether its can­di­date, dis­cov­ered by BioN­Tech, meets the reg­u­la­to­ry stan­dards for emer­gency use au­tho­riza­tion by Oc­to­ber. But more than 60 lead­ing re­searchers and bioethi­cists are urg­ing them to wait.

In a let­ter first re­port­ed by Bloomberg Law, the promi­nent group of sci­en­tists ar­gued that un­der a rig­or­ous safe­ty stan­dard, all 30,000 tri­al par­tic­i­pants should be mon­i­tored for a min­i­mum of two months af­ter re­ceiv­ing the sec­ond dose of the vac­cine. Since many in the Pfiz­er tri­al have not yet re­ceived that sec­ond dose, in­ves­ti­ga­tors should keep mon­i­tor­ing them un­til at least late No­vem­ber be­fore the com­pa­ny files for an EUA, they ar­gued.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.